Metabolic Evaluation
We look for metabolic and medical factors that may be contributing to weight gain or making weight loss more difficult.
Understand the medical, metabolic, behavioral, and lifestyle factors affecting your weight—and build an individualized plan with ongoing clinical support.
Weight gain and difficulty losing weight can have many contributing factors. Appetite, insulin resistance, thyroid function, hormones, sleep, stress, medications, nutrition, activity, aging, and other medical conditions can all influence metabolism and body composition.
We look for metabolic and medical factors that may be contributing to weight gain or making weight loss more difficult.
Thyroid and other hormone-related factors may be evaluated when symptoms, history, or clinical findings warrant testing.
Nutrition, activity, sleep, stress, behavioral patterns, and muscle preservation remain important parts of treatment.
GLP-1 therapy is only one option. Your provider may consider several medication classes depending on your individual needs.
Two people with the same weight may have very different metabolic profiles, medical histories, hormone status, medications, barriers, and treatment needs.
Review weight trends, previous strategies, medications, medical conditions, family history, appetite, sleep, activity, and relevant symptoms.
Assessment may include blood sugar, insulin resistance, lipids, thyroid function, hormones, blood pressure, body composition, and clinically appropriate laboratory testing.
Discuss realistic goals, nutrition, activity, prescription options, potential benefits and risks, insurance coverage, monitoring, and affordability.
Effective medical weight management is rarely one-dimensional. Your treatment plan is selected and adjusted according to your health, metabolic factors, goals, response, tolerability, and preferences.
We do not assume that every patient needs semaglutide or tirzepatide. Medication is one tool within a broader medical weight-management strategy.
Medication selection may take into account your metabolic health, body-mass index, weight-related conditions, cardiovascular history, blood pressure, gastrointestinal history, psychiatric history, pregnancy potential, current medications, contraindications, previous treatment response, insurance coverage, and individual goals.
Semaglutide acts on the GLP-1 receptor. FDA-approved products include Wegovy® for approved weight-management indications and Ozempic® for approved type 2 diabetes indications.
Tirzepatide acts on both GIP and GLP-1 receptors. FDA-approved products include Zepbound® for approved weight-management indications and Mounjaro® for type 2 diabetes.
GLP-1 and dual GIP + GLP-1 medications are not the only prescription options. Depending on your medical history and treatment goals, your provider may consider other established prescription therapies when appropriate.
An appetite-suppressant medication that may be considered for selected patients after appropriate cardiovascular and medical evaluation.
A prescription combination of phentermine and extended-release topiramate used for chronic weight management in appropriate patients.
A prescription combination of naltrexone and bupropion that may help address appetite and food cravings in appropriately selected patients.
Other medications or treatment strategies may be considered according to your health history, previous response, and clinical needs.
In some patients, addressing an underlying metabolic, thyroid, hormonal, sleep-related, medication-related, or behavioral contributor may be just as important as choosing a weight-management medication.
Our goal is not simply to prescribe a medication. It is to understand the factors affecting your weight and build a treatment plan that makes sense for your health.
When legally permitted and clinically appropriate, a provider may discuss compounded semaglutide or compounded tirzepatide for an individual patient whose medical needs cannot be met by an available FDA-approved medication.
Compounded medications are prepared through appropriately licensed pharmacies. They are not FDA-approved products and are different from FDA-approved branded medications.
For eligible patients, compounded weight-management medications start at $249 per month, with medical management included.
We can review insurance benefits for eligible FDA-approved medications and discuss self-pay options when appropriate.
We can review your benefits and determine whether an appropriate FDA-approved weight-management medication may be covered under your plan.
When your insurance plan requires prior authorization, our team can help submit the relevant clinical information and supporting documentation for review.
Depending on your diagnosis, medical history, eligibility, and benefits, we may pursue coverage for an appropriate FDA-approved medication such as Wegovy®, Zepbound®, Qsymia®, Contrave®, or another covered treatment when clinically indicated.
Our goal is to help you understand your benefits and make the most of available insurance coverage before deciding on your expected out-of-pocket treatment cost.
Tirzepatide acts on both GIP and GLP-1 receptors. Treatment is individualized based on response, tolerability, goals, medical history, and clinical needs.
FDA-approved tirzepatide dosing begins at 2.5 mg once weekly for the first 4 weeks, followed by 5 mg once weekly. Additional increases may be considered in 2.5 mg increments after at least 4 weeks at the current dose.
You do not automatically need to increase your dose every month or progress through every dose level. Your provider may recommend remaining at an effective, well-tolerated dose or adjusting treatment based on appetite control, weight-management response, side effects, goals, and individual needs.
This chart shows FDA-approved tirzepatide dosing for general education. Your provider will give you your individual dosing instructions. Compounded tirzepatide is not FDA-approved and is different from Zepbound® and Mounjaro®.
Semaglutide acts on the GLP-1 receptor. Treatment typically begins at a low dose and may be increased gradually based on tolerability, response, goals, and individual medical needs.
Standard injectable Wegovy® titration begins at 0.25 mg once weekly and generally progresses gradually through higher doses. A 7.2 mg Wegovy® injection dose is also an FDA-approved higher-dose option for certain adults.
Dose escalation is individualized. Your provider may recommend remaining at a lower dose when it is providing an appropriate response and is well tolerated, or may adjust treatment based on appetite control, response, side effects, goals, and clinical needs.
This chart shows FDA-approved semaglutide dosing for general education. Your provider will give you your individual dosing instructions. Compounded semaglutide is not FDA-approved and is different from Wegovy® and Ozempic®.
Follow-up allows your provider to assess your metabolic health, progress, body composition, medication response, side effects, barriers, and whether your treatment plan remains appropriate.
Review your medical history, metabolic factors, hormones when indicated, medications, risks, and goals.
Build a treatment plan using the nutrition, lifestyle, medical, and medication strategies appropriate for you.
Follow weight trends, body composition, metabolic markers, symptoms, medication response, and tolerability.
Refine medication, dosing, nutrition, and other components as your health and treatment needs evolve.
Medical weight management should address the whole clinical picture. We help identify relevant metabolic and hormonal factors, compare treatment options, explore insurance coverage, monitor your response, and refine your plan as your health and needs change.
Meet with an Alpha Hormones® medical provider to review your weight history, metabolic health, hormones when appropriate, nutrition and lifestyle factors, current medications, insurance benefits, and the treatment options that may be appropriate for you.
This page is for general education. Your treatment, medication, dose, and monitoring are individualized after medical evaluation. Insurance coverage is not guaranteed, and compounded medications are not FDA-approved. Pricing and availability may change.